Anal cancer

The European Medicines Agency ( EMA ) has approved Lynparza ( Olaparib ) tablets ( 300mg twice daily ) for...


The European Commission ( EC ) has approved Cabometyx ( Cabozantinib ) 20, 40, 60 mg for the first-line treatment...


Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...


The phase 3 PROSPER trial has showed a statistically significant improvement in metastasis-free survival ( MFS ) with Enzalutamide (...


The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the...


ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell...


CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab...


CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy...


The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...


The FDA ( U.S. Food and Drug Administration ) has approved Lumoxiti ( Moxetumomab pasudotox-tdfk ) injection for intravenous use...


The European Commission has approved Tafinlar ( Dabrafenib ) in combination with Mekinist ( Trametinib ) for the adjuvant treatment...


The results from an interim analysis of KEYNOTE-057, a phase 2 trial evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy,...


The pivotal phase 3 KEYNOTE-426 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Axitinib ( Inlyta...


The Food and Drug Administration ( FDA ) has approved Osimertinib ( Tagrisso ) for the first-line treatment of patients...


The PROSPER trial has shown a clinically and statistically significant improvement in metastasis-free survival ( hazard ratio, HR=0.292 [ 95%...


Role of aromatase inhibitors and Zoledronic acid ( Zometa ) as adjuvant treatment of premenopausal endocrine-responsive breast cancer patients is...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination...


Programmed cell death protein ligand-1 ( PD-L1 ) inhibitors are novel anti-cancer therapies but are associated with potentially therapy limiting...


The FDA ( U.S. Food and Drug Administration ) has approved Larotrectinib ( Vitrakvi ), the first oral TRK inhibitor. The...